Sensei Biotherapeutics (SNSE)
(Delayed Data from NSDQ)
$1.53 USD
-0.06 (-3.77%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.58 +0.05 (3.27%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SNSE 1.53 -0.06(-3.77%)
Will SNSE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SNSE based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for SNSE
Buy Rating Justified for Sensei Biotherapeutics Amidst Strong Pipeline and Financial Stability
Sensei Biotherapeutics initiated with bullish view at Stephens, here's why
EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member
Sensei Biotherapeutics Poised for Growth: A Strong Buy Rating Amid Financial Stability and Promising Clinical Trials
SNSE Stock Earnings: Sensei Biotherapeutics Misses EPS for Q1 2024